Only one combination treatment in advanced HCC, atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF), has received full FDA approval as a first-line therapy in HCC, while three regimens, nivolumab and pembrolizumab (both anti-PD-1) monotherapy and nivolumab with ipilimumab, have received accelerated approvals [18]. The gene discussed is CD274; the disease is hepatocellular carcinoma.